<DOC>
	<DOCNO>NCT00977210</DOCNO>
	<brief_summary>The purpose study establish Maximum Tolerated Dose ( MTD ) OXi4503 give weekly infusion patient advance solid tumor .</brief_summary>
	<brief_title>Safety Study OXi4503 ( Vascular Disrupting Agent ) Given 3 x Weekly Intravenous Infusions Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically proven cancer . Written informed consent . Age &gt; /= 18 year . Life expectancy least 12 week . World Health Organization ( WHO ) performance status 0 1 . Adequate Hematological biochemical index support investigational therapy . All woman childbearing potential ( WOCBP ) must negative serum pregnancy test . WOCBP fertile men partner must agree use effective form contraception study 90 day last dose study medication . Measurable evaluable disease . All toxic manifestation previous treatment must resolve . Able undergo MRI scanning . Radiotherapy , endocrine therapy , immunotherapy chemotherapy previous four week ( six week nitrosureas MitomycinC ) prior treatment . Pregnant lactating woman . Major thoracic and/or abdominal surgery precede four week patient yet recover . Patients active uncontrolled infection . Patients condition Investigator 's opinion would make patient good candidate clinical trial . Patients know serologically positive Hepatitis B , Hepatitis C Human Immunodeficiency Virus ( HIV ) . Previous ongoing cardiac condition . Uncontrolled hypertension . Patients take drug know prolong QTc interval . Patients ischaemic vascular damage previous radiotherapy . Patients take warfarin heparin . Patients take naproxen . Patients take supplement multivitamin contain vitamin C. Patients take investigational drug duration study . Patients brain metastasis neurological tissue involvement spinal column .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>oxi4503</keyword>
	<keyword>oxigene</keyword>
	<keyword>cruk</keyword>
	<keyword>solid tumor</keyword>
	<keyword>VDA</keyword>
	<keyword>vascular disrupting agent</keyword>
</DOC>